Management of autoimmune hepatitis

Current Opinion in Gastroenterology

Volumn 27, Issue 3, 2011, Pages 224-230

  Mayo, Marlyn J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

autoimmune; azathioprine; budesonide; diagnosis; hepatitis; mycophenolate; prednisone; tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; AZATHIOPRINE; BUDESONIDE; CYTOCHROME P450; DICLOFENAC; GAMMA GLUTAMYLTRANSFERASE; GLOBULIN; LACTATE DEHYDROGENASE; MELOXICAM; METHYLDOPA; MICROSOME ANTIBODY; MINOCYCLINE; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID; NITROFURANTOIN; OXYPHENISATINE; PREDNISOLONE; PREDNISONE; SMOOTH MUSCLE ANTIBODY; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; TIENILIC ACID; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; AUTOIMMUNE HEPATITIS; BONE GROWTH; CLINICAL FEATURE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; HEPATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LOW DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; REMISSION; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

AZATHIOPRINE; BUDESONIDE; DRUG HYPERSENSITIVITY; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 79955060387     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283457ce0     Document Type: Article

References (59)

1. James DG. Waldenstrom's syndromes. Q J Med 2010; 103:67-68.
2. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40:159-185.
3. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1:735-737.
4. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63:820-833.
5. Wright EC, Seeff LB, Berk PD, et al. Treatment of chronic active hepatitis. An analysis of three controlled trials. Gastroenterology 1977; 73:1422-1430. (Pubitemid 8229303)
6. Dienes HP, Drebber U. Pathology of immune-mediated liver injury. Dig Dis 2010; 28:57-62.
7. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 2010; 34:7-14.
8. Teufel A, Weinmann A, Kahaly GJ, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 2010; 44:208-213.
9. Kogan J, Safadi R, Ashur Y, et al. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002; 35:75-81. (Pubitemid 34663355)
10. Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42:53-62. (Pubitemid 40911311)
11. Werner M, Wallerstedt S, Lindgren S, et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol 2010; 45:457-467.
12. Seki S, Kitada T, Iwai S, et al. Immunohistochemical detection of Fas and apoptosis in type-1 autoimmune hepatitis. Hepatogastroenterology 2003; 50:1274-1277. (Pubitemid 37186463)
13. Kahraman A, Gerken G, Canbay A. Apoptosis in immune-mediated liver diseases. Dig Dis 2010; 28:144-149.
14. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43:532-538.
15. Boberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996; 23:1369-1376. (Pubitemid 26181218)
16. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2004; 99:1316-1320. (Pubitemid 39062269)
17. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21:613-619.
18. Lidman K, Biberfeld G, Fagraeus A, et al. Antiactin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 1976; 24:266-272.
19. Duchini A, McHutchison JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol 2000; 95:3238-3241.
20. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6:467-486.
21. Graziadei IW, Obermoser GE, Sepp NT, et al. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 2003; 12:409-412. (Pubitemid 36596987)
22. Abe M, Furukawa S, Takayama S, et al. Drug-induced hepatitis with autoimmune features during minocycline therapy. Intern Med 2003; 42:48-52. (Pubitemid 36267664)
23. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51:2040-2048.
24. Mancini S, Amorotti E, Vecchio S, et al. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010; 5:193-200.
25. Goujon C, Dahel K, Borard F, et al. Autoimmune hepatitis in two psoriasis patients treated with infliximab. J Am Acad Dermatol 2010; 63:e43-e44.
26. Adar T, Mizrahi M, Pappo O, et al. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010; 44:e20-e22.
27. Primo J, Michavila J, Jimenez I. Efalizumab-induced autoimmune hepatitis. Gastroenterol Hepatol 2010; 33:69-70.
28. Martinez-Odriozola P, Gutierrez-Maceas A, Ibarmia-Lahuerta J, Muiz-Sanchez J. Meloxicam as a cause of drug-induced autoimmune hepatitis. Dig Dis Sci 2010; 55:1191-1192.
29. Kamiyama T, Nouchi T, Kojima S, et al. Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 1997; 92:703-704. (Pubitemid 27184395)
30. Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3. Cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993; 38:744-751. (Pubitemid 23121285)
31. Volkmann M, Martin L, Baurle A, et al. Soluble liver antigen: isolation of a 35-kD recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology 2001; 33:591-596. (Pubitemid 32185221)
32. Volkmann M, Luithle D, Zentgraf H, et al. SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. J Autoimmun 2010; 34:59-65.
33. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000; 33:208-215. (Pubitemid 30485224)
34. Terjung B, Bogsch F, Klein R, et al. Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC-and multivariate regression analysis. Eur J Med Res 2004; 9:439-448.
35. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31:929-938. (Pubitemid 29514229)
36. Poulsen LO, Thulstrup AM, Mellemkjaer L, et al. Mortality and causes of death in patients with lupoid hepatitis. A long-term follow-up study in Denmark. Dan Med Bull 2002; 49:263-265.
37. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009; 29:816-823.
38. Manns MP, Czaja AJ, Gorham JD, et al. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193-2213.
39. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003; 23:116-123. (Pubitemid 37265783)
40. Verma S, Gunuwan B, Mendler M, et al. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99:1510-1516. (Pubitemid 39180099)
41. Ebbeson RL, Schreiber RA. Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful? Clin Gastroenterol Hepatol 2004; 2:935-940. (Pubitemid 39335801)
42. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48:169-176. (Pubitemid 351975541)
43. Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009; 50:538-545.
44. Neuhauser M, Bjornsson E, Treeprasertsuk S, et al. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol 2010; 105:345-353.
45. Miyake Y, Iwasaki Y, Kobashi H, et al. Clinical features of autoimmune hepatitis diagnosed based on simplified criteria of the International Autoimmune Hepatitis Group. Dig Liver Dis 2010; 42:210-215.
46. Langley PG, Underhill J, Tredger JM, et al. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002; 37:441-447.
47. Nguyen TM, Daubard M, Le Gall C, et al. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis. Ther DrugMonit 2010; 32:433-437.
48. Hindorf U, Jahed K, Bergquist A, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010; 52:106-111.
49. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46:1321-1327. (Pubitemid 32523281)
50. Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis 2002; 22:379-386.
51. Czaja AJ, Freese DK, American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36:479-497.
52. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999; 30:1381-1386.
53. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103:3063-3070.
54. Larsen FS, Clemmesen JO, Clausen M, et al. A randomized, controlled trial of mycophenolate mofetil versus azathioprine therapy for patients with de novo autoimmune hepatitis with 24 months of follow up. Hepatology 2008; 48:1089A.
55. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90:771-776.
56. Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38:805-809. (Pubitemid 39274185)
57. Wiegand J, Schüler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25:927-934. (Pubitemid 41404011)
58. Csepregi A, Röcken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006; 12:1362-1366.
59. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139:1198-1206.